Advertisement: TTP Killer 50
24 March, 2022 - 08:32 By Tony Quested

Arecor wins key US patent milestone for diabetes products

Cambridge’s Arecor Therapeutics plc has won a key patent approval in the US as it turns its IP portfolio into a veritable pharma fortress.

The United States Patent and Trademark Office has granted a patent protecting novel formulations of the group’s proprietary insulin products, AT247 and AT278.

Arecor has invested in building a strong patent portfolio to protect the Arestat™ technology platform and its proprietary pipeline products. The Aim-listed group’s intellectual property portfolio currently comprises 36 patent families, including >50 granted patents in Europe, the US and in other key territories.

As part of this strategy, Arecor has robust IP directed to the novel insulin compositions that protect different aspects of AT247 and AT278 formulations, as well as their specific properties and methods of use. 

Arecor’s strategy is to generate a fortress of both narrow and broad inter-related IP rights that cover the features of these products. US11278624 is the first granted US patent within the group’s comprehensive insulin IP strategy.

Dr Jan Jezek, chief scientific officer at Arecor, said: “Arecor’s novel insulin products, based on a combination of existing insulin analogues and our highly innovative formulation science, have potential to improve convenience, compliance and enable more effective management of blood glucose for people living with type 1 and type 2 diabetes. 

“As the clinical validation of the superiority of these products compared to current gold standard prandial insulins continues, we are also advancing the intellectual property protection for these products. 

“This recently granted US patent, the first within the group’s comprehensive insulin IP strategy, is a significant milestone, and we will continue to strengthen our IP portfolio with additional patent applications already in progress.”

Arecor is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. 

Arecor leverages the Arestat™ technology in partnerships with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of its therapeutic products under a technology licensing model.

Newsletter Subscription

Stay informed of the latest news and features